Drug delivery targets and systems for targeted treatment of rheumatoid arthritis

Feng, Xun; Chen, Yang

doi:10.1080/1061186x.2018.1433680

Cited by 64 publications

(46 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Those advantages are related, for instance, with the improvement of the insoluble drug delivery, maximizing the bioavailability, and the treatment efficacy. Furthermore, the use of biomaterials can help to reduce secondary effects and enhance the plasma half-life of peptide drugs by protecting them from degradation caused by the environment [7,8].…”

Section: Introductionmentioning

confidence: 99%

Enzymatically crosslinked tyramine-gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment

Oliveira

Gonçalves

Shin

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint synovial inflammation, as well as cartilage and bone tissue destruction. Current strategies for the treatment of RA can reduce joint inflammation, but the treatment options still represent stability concerns since they are not sufficient and present a fast clearing. Thus, several drug delivery systems (DDS) have been advanced to tackle this limitation. Injectable gellan gum (GG) hydrogels, reduced by physical crosslinking methods, also being proposed as DDS, but this kind of crosslinking can produce hydrogels that become weaker in physiological conditions. Nevertheless, enzymatic crosslinking emerged as an alternative to increase mechanical strength, which can be adjusted by the degree of enzymatic crosslinking. In this study, tyramine-modified gellan gum (Ty-GG) hydrogels were developed via horseradish peroxidase (HRP) crosslinking; and betamethasone was encapsulated within, to increase the specificity and safety in the treatment of patients with RA. Physicochemical results showed that it was possible to modify GG with tyramine, with a degree of substitution of approximately 30%. They showed high mechanical strength and resistance, presenting a controlled betamethasone release profile over time. Ty-GG hydrogels also exhibited no cytotoxic effects and do not negatively affected the metabolic activity and proliferation of chondrogenic primary cells. Furthermore, the main goal was achieved since betamethasone-loaded Ty-GG hydrogels demonstrated to have a more effective therapeutic effect when compared with the administration of betamethasone alone. Therefore, the developed Ty-GG hydrogels represent a promising DDS and a reliable alternative to traditional treatments in patients with RA.

show abstract

Section: Introductionmentioning

confidence: 99%

Enzymatically crosslinked tyramine-gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment

Oliveira

Gonçalves

Shin

et al. 2020

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

“…To overcome the obstacles described above in the application of GCs in the treatment of RA, many nanomedicines have been developed (Feng & Chen, 2018;Gauthier et al, 2018;Knudsen et al, 2015;Krakovičová, Etrych, & Ulbrich, 2009;Silva, Lopes, Lobo, & Amaral, 2015;Qin Wang et al, 2016). They are all aiming to efficiently load GCs, target specific tissues or cell types, and control drug release for a long period of time (Lühder & Reichardt, 2017;Q Wang & Sun, 2017) as summarized in Table I.…”

Section: Nanomedicines For Glucocorticoidsmentioning

confidence: 99%

Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis

Reynaud

Lorscheider

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 0.5 to 1% of the world population. Current treatments include on one hand non-steroidal anti-inflammatory drugs and glucocorticoids (GCs) for treating pain and on the other hand disease-modifying anti-rheumatic drugs such as methotrexate, Janus kinase inhibitors or biologics such as antibodies targeting mainly cytokine expression. More recently, nucleic acids such as siRNA, miRNA or anti-miRNA have shown strong potentialities for the treatment of RA. This review discusses the way nanomedicines can target GCs and nucleic acids to inflammatory sites, increase drug penetration within inflammatory cells, achieve better subcellular distribution and finally protect drugs against degradation. For GCs such a targeting effect would allow the treatment to be more effective at lower doses and to reduce the administration frequency as well as to induce much fewer side-effects. In the case of nucleic acids, particularly siRNA, knocking down proteins involved in RA, could importantly be facilitated using nanomedicines. Finally, the combination of both siRNA and GCs in the same carrier allowed for the same cell to target both the GCs receptor as well as any other signaling pathway involved in RA. Nanomedicines appear to be very promising for the delivery of conventional and novel drugs in RA therapeutics.

show abstract

“…At the same time, activated synovial cells release vascular endothelial growth factors (VEGFs), resulting in angiogenesis. This is the so-called “pannus of synovium” (Marrelli et al, 2011 ; Feng and Chen, 2018 ). Pannus promotes the transfer of inflammatory cells into the joints to exacerbate arthritis.…”

Section: Introductionmentioning

confidence: 99%

Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment

Wang

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is characterized by synovial hyperplasia and cartilage/bone destruction, which results in a high disability rate on human health and a huge burden on social economy. At present, traditional therapies based on drug therapy still cannot cure RA, in accompany with the potential serious side effects. Based on the development of nanobiotechnology and nanomedicine, energy conversion-based nanotherapy has demonstrated distinctive potential and performance in RA treatment. This strategy employs specific nanoparticles with intrinsic physiochemical properties to target lesions with the following activation by diverse external stimuli, such as light, ultrasound, microwave, and radiation. These nanoagents subsequently produce therapeutic effects or release therapeutic factors to promote necrotic apoptosis of RA inflammatory cells, reduce the concentration of related inflammatory factors, relieve the symptoms of RA, which are expected to ultimately improve the life quality of RA patients. This review highlights and discusses the versatile biomedical applications of energy conversion-based nanotherapy in efficient RA treatment, in together with the deep clarification of the facing challenges and further prospects on the final clinical translations of these energy conversion-based nanotherapies against RA.

show abstract

Drug delivery targets and systems for targeted treatment of rheumatoid arthritis

Cited by 64 publications

References 130 publications

Enzymatically crosslinked tyramine-gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment

Enzymatically crosslinked tyramine-gellan gum hydrogels as drug delivery system for rheumatoid arthritis treatment

Nanomedicines for the delivery of glucocorticoids and nucleic acids as potential alternatives in the treatment of rheumatoid arthritis

Energy Conversion-Based Nanotherapy for Rheumatoid Arthritis Treatment

Contact Info

Product

Resources

About